thesis
Clinical and pharmacological studies on the topoisomerase I inhibitor topotecan
- Publication date
- 13 March 1996
- Publisher
- During the 1950's the National Cancer Institute (NCI) started a screening
program of natural products. Among the thousands of plants analyzed, campto·
thecin, a plant alkaloid extract from the Camptotheca acuminata, an oriental tree
which is cultivated throughout Asia, was found to be active against L 1210
murine leukemia. In the early 1970's camptothecin underwent clinical
testing. Although antitumor activity was observed in patients with colorectal
cancer, melanoma and non-small-cell lung cancer further clinical development
was precluded because of severe and unpredictable toxicities including, myelosuppression,
diarrhea and hemorrhagic cystitis. In the mid 1980's several
developments renewed the interest in camptothecin. Firstly, Hsiang et al.
identified topoisomerase I as the specific intracellular target of camptothecin.
Secondly, overexpressed topoisomerase I level was found in advanced stages of
human colon adenocarcinoma and other malignancies but not in normal tissue. This resulted in the development of several semisynthetic camptothecin
analogues with more predictable toxicity profiles and consistent antitumor
activity. One of these analogues is topotecan (SKF 104864, NSC 609699, (s)-9-
dimethylaminomethyl-10-hydroxycamptothecin, Hycamtin®) which in preclinical
studies demonstrated broad spectrum antitumor activity (10,11). Phase I studies
revealed that topotecan was very well tolerated with generally a brief and noncumulative
neutropenia being the dose-limiting toxicity on all schedules (12,13).
Major responses were observed in carcinomas of the ovary, lung (both small and
non-small), oesophagus and colon. Phase II studies were initiated with a daily x5
schedule based on the fact that most objective responses in phase I studies
were observed with this schedule.
This thesis includes clinical and pharmacological studies on topotecan which
was focused towards the efficacy of the daily x5 schedule in patients with
colorectal and ovarian cancer and towards the concept of prolonged exposure to
the drug.